344 related articles for article (PubMed ID: 31371342)
1. Anti-OX40 Antibody Directly Enhances The Function of Tumor-Reactive CD8
Peng W; Williams LJ; Xu C; Melendez B; McKenzie JA; Chen Y; Jackson HL; Voo KS; Mbofung RM; Leahey SE; Wang J; Lizee G; Tawbi HA; Davies MA; Hoos A; Smothers J; Srinivasan R; Paul EM; Yanamandra N; Hwu P
Clin Cancer Res; 2019 Nov; 25(21):6406-6416. PubMed ID: 31371342
[TBL] [Abstract][Full Text] [Related]
2. Enhancing the Generation of Eomes
Emerson DA; Rolig AS; Redmond WL
Cancer Immunol Res; 2021 Apr; 9(4):430-440. PubMed ID: 33593794
[TBL] [Abstract][Full Text] [Related]
3. Timing of PD-1 Blockade Is Critical to Effective Combination Immunotherapy with Anti-OX40.
Messenheimer DJ; Jensen SM; Afentoulis ME; Wegmann KW; Feng Z; Friedman DJ; Gough MJ; Urba WJ; Fox BA
Clin Cancer Res; 2017 Oct; 23(20):6165-6177. PubMed ID: 28855348
[No Abstract] [Full Text] [Related]
4. FcγRIIB engagement drives agonistic activity of Fc-engineered αOX40 antibody to stimulate human tumor-infiltrating T cells.
Campos Carrascosa L; van Beek AA; de Ruiter V; Doukas M; Wei J; Fisher TS; Ching K; Yang W; van Loon K; Boor PPC; Rakké YS; Noordam L; Doornebosch P; Grünhagen D; Verhoef K; Polak WG; IJzermans JNM; Ni I; Yeung YA; Salek-Ardakani S; Sprengers D; Kwekkeboom J
J Immunother Cancer; 2020 Sep; 8(2):. PubMed ID: 32900860
[TBL] [Abstract][Full Text] [Related]
5. Radiation Augments the Local Anti-Tumor Effect of
Pieper AA; Zangl LM; Speigelman DV; Feils AS; Hoefges A; Jagodinsky JC; Felder MA; Tsarovsky NW; Arthur IS; Brown RJ; Birstler J; Le T; Carlson PM; Bates AM; Hank JA; Rakhmilevich AL; Erbe AK; Sondel PM; Patel RB; Morris ZS
Front Immunol; 2021; 12():763888. PubMed ID: 34868010
[TBL] [Abstract][Full Text] [Related]
6. The small molecule TGF-β signaling inhibitor SM16 synergizes with agonistic OX40 antibody to suppress established mammary tumors and reduce spontaneous metastasis.
Garrison K; Hahn T; Lee WC; Ling LE; Weinberg AD; Akporiaye ET
Cancer Immunol Immunother; 2012 Apr; 61(4):511-21. PubMed ID: 21971588
[TBL] [Abstract][Full Text] [Related]
7. OX40 ligation enhances primary and memory cytotoxic T lymphocyte responses in an immunotherapy for hepatic colon metastases.
Pan PY; Zang Y; Weber K; Meseck ML; Chen SH
Mol Ther; 2002 Oct; 6(4):528-36. PubMed ID: 12377195
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy Expands and Maintains the Function of High-Affinity Tumor-Infiltrating CD8 T Cells In Situ.
Moran AE; Polesso F; Weinberg AD
J Immunol; 2016 Sep; 197(6):2509-21. PubMed ID: 27503208
[TBL] [Abstract][Full Text] [Related]
9. Anti-OX40 stimulation in vivo enhances CD8+ memory T cell survival and significantly increases recall responses.
Ruby CE; Redmond WL; Haley D; Weinberg AD
Eur J Immunol; 2007 Jan; 37(1):157-66. PubMed ID: 17183611
[TBL] [Abstract][Full Text] [Related]
10. Intratumoral CD4+ T lymphodepletion sensitizes poorly immunogenic melanomas to immunotherapy with an OX40 agonist.
Fujiwara S; Nagai H; Shimoura N; Oniki S; Yoshimoto T; Nishigori C
J Invest Dermatol; 2014 Jul; 134(7):1884-1892. PubMed ID: 24468748
[TBL] [Abstract][Full Text] [Related]
11. Combined targeting of costimulatory (OX40) and coinhibitory (CTLA-4) pathways elicits potent effector T cells capable of driving robust antitumor immunity.
Redmond WL; Linch SN; Kasiewicz MJ
Cancer Immunol Res; 2014 Feb; 2(2):142-53. PubMed ID: 24778278
[TBL] [Abstract][Full Text] [Related]
12. In vivo antitumor function of tumor antigen-specific CTLs generated in the presence of OX40 co-stimulation in vitro.
Pham Minh N; Murata S; Kitamura N; Ueki T; Kojima M; Miyake T; Takebayashi K; Kodama H; Mekata E; Tani M
Int J Cancer; 2018 Jun; 142(11):2335-2343. PubMed ID: 29313971
[TBL] [Abstract][Full Text] [Related]
13. Combination OX40 agonism/CTLA-4 blockade with HER2 vaccination reverses T-cell anergy and promotes survival in tumor-bearing mice.
Linch SN; Kasiewicz MJ; McNamara MJ; Hilgart-Martiszus IF; Farhad M; Redmond WL
Proc Natl Acad Sci U S A; 2016 Jan; 113(3):E319-27. PubMed ID: 26729864
[TBL] [Abstract][Full Text] [Related]
14. Defects in the acquisition of CD8 T cell effector function after priming with tumor or soluble antigen can be overcome by the addition of an OX40 agonist.
Redmond WL; Gough MJ; Charbonneau B; Ratliff TL; Weinberg AD
J Immunol; 2007 Dec; 179(11):7244-53. PubMed ID: 18025166
[TBL] [Abstract][Full Text] [Related]
15. Ligation of the OX40 co-stimulatory receptor reverses self-Ag and tumor-induced CD8 T-cell anergy in vivo.
Redmond WL; Gough MJ; Weinberg AD
Eur J Immunol; 2009 Aug; 39(8):2184-94. PubMed ID: 19672905
[TBL] [Abstract][Full Text] [Related]
16. OX40 is a potent immune-stimulating target in late-stage cancer patients.
Curti BD; Kovacsovics-Bankowski M; Morris N; Walker E; Chisholm L; Floyd K; Walker J; Gonzalez I; Meeuwsen T; Fox BA; Moudgil T; Miller W; Haley D; Coffey T; Fisher B; Delanty-Miller L; Rymarchyk N; Kelly T; Crocenzi T; Bernstein E; Sanborn R; Urba WJ; Weinberg AD
Cancer Res; 2013 Dec; 73(24):7189-7198. PubMed ID: 24177180
[TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant anti-OX40 (MEDI6469) therapy in patients with head and neck squamous cell carcinoma activates and expands antigen-specific tumor-infiltrating T cells.
Duhen R; Ballesteros-Merino C; Frye AK; Tran E; Rajamanickam V; Chang SC; Koguchi Y; Bifulco CB; Bernard B; Leidner RS; Curti BD; Fox BA; Urba WJ; Bell RB; Weinberg AD
Nat Commun; 2021 Feb; 12(1):1047. PubMed ID: 33594075
[TBL] [Abstract][Full Text] [Related]
18. OX40 Agonist Tumor Immunotherapy Does Not Impact Regulatory T Cell Suppressive Function.
Polesso F; Sarker M; Weinberg AD; Murray SE; Moran AE
J Immunol; 2019 Oct; 203(7):2011-2019. PubMed ID: 31434709
[TBL] [Abstract][Full Text] [Related]
19. Concurrent PD-1 Blockade Negates the Effects of OX40 Agonist Antibody in Combination Immunotherapy through Inducing T-cell Apoptosis.
Shrimali RK; Ahmad S; Verma V; Zeng P; Ananth S; Gaur P; Gittelman RM; Yusko E; Sanders C; Robins H; Hammond SA; Janik JE; Mkrtichyan M; Gupta S; Khleif SN
Cancer Immunol Res; 2017 Sep; 5(9):755-766. PubMed ID: 28848055
[TBL] [Abstract][Full Text] [Related]
20. Science gone translational: the OX40 agonist story.
Weinberg AD; Morris NP; Kovacsovics-Bankowski M; Urba WJ; Curti BD
Immunol Rev; 2011 Nov; 244(1):218-31. PubMed ID: 22017441
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
